Introduction of laser technology and procedure use for benign prostatic hyperplasia: data from Florida
- PMID: 22840735
- PMCID: PMC3429633
- DOI: 10.1016/j.urology.2012.05.025
Introduction of laser technology and procedure use for benign prostatic hyperplasia: data from Florida
Abstract
Objective: To examine the association of laser technology adoption in a market with surgery rates for benign prostatic hyperplasia.
Methods: Using the Florida files from the State Ambulatory and Inpatient Surgery Databases (2001-2009), we identified all patients who underwent transurethral surgery for benign prostatic hyperplasia. We calculated rates of benign prostatic hyperplasia surgery for all markets within the state (defined by Hospital Service Area) over time. Markets were split into 3 categories: (1) Always offering, (2) never offering, or (3) initially not offering but adopting laser prostatectomy after 2001. We used multivariable regression models to estimate surgery rates adjusted for other market characteristics. Interaction terms were included in the models to examine differences in time trends between market categories.
Results: After adjusting for market characteristics, time trends differed by market category (P < .001). Surgery rates decreased from 318 to 248 procedures per 100,000 men in markets always offering laser prostatectomy (P < .001). Markets never offering laser surgery had much lower rates that remained stable (180-187 procedures per 100,000 men, P = .805). In markets adopting laser technology, rates increased from 268 to 296 procedures per 100,000 men after adoption (P = .044), such that 4 years after adoption these markets had the highest rates among the 3 categories.
Conclusion: Adoption of laser technology is associated with rising rates of surgical intervention for benign prostatic hyperplasia. This trend appears to be induced by the introduction of laser surgery.
Copyright © 2012 Elsevier Inc. All rights reserved.
Figures
Similar articles
-
Differential adoption of laser prostatectomy for treatment of benign prostatic hyperplasia.Urology. 2013 Jun;81(6):1177-82. doi: 10.1016/j.urology.2013.01.051. Epub 2013 Mar 19. Urology. 2013. PMID: 23522295 Free PMC article.
-
Population based trends in the surgical treatment of benign prostatic hyperplasia.J Urol. 2012 Nov;188(5):1837-41. doi: 10.1016/j.juro.2012.07.049. Epub 2012 Sep 19. J Urol. 2012. PMID: 22999698 Free PMC article.
-
[Where do we stand with benign prostatic hyperplasia day-case surgery: A laser effect?].Prog Urol. 2018 Sep;28(10):509-514. doi: 10.1016/j.purol.2018.05.005. Epub 2018 Jun 12. Prog Urol. 2018. PMID: 29907496 French.
-
Management of Benign Prostatic Hyperplasia Larger than 100 ml: Simple Open Enucleation Versus Transurethral Laser Prostatectomy.Curr Urol Rep. 2016 Jun;17(6):44. doi: 10.1007/s11934-016-0601-7. Curr Urol Rep. 2016. PMID: 27048160 Review.
-
Minimally invasive surgery in the management of benign prostatic hyperplasia.Minerva Urol Nefrol. 2009 Sep;61(3):269-89. Minerva Urol Nefrol. 2009. PMID: 19773728 Review.
References
-
- Saigal CS, Joyce G. Economic costs of benign prostatic hyperplasia in the private sector. J. Urol. 2005;173:1309–1313. - PubMed
-
- Platz EA, Smit E, Curhan GC, et al. Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in U.S. men. Urology. 2002;59:877–883. - PubMed
-
- Taub DA, Wei JT. The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the united states. Curr Urol Rep. 2006;7:272–281. - PubMed
-
- Saigal CS, Movassaghi M, Pace J, et al. Economic Evaluation of Treatment Strategies for Benign Prostatic Hyperplasia--Is Medical Therapy More Costly in the Long Run? J. Urol. 2007;177:1463–1467. - PubMed
-
- Wennberg JE, Mulley AG, Jr, Hanley D, et al. An assessment of prostatectomy for benign urinary tract obstruction. Geographic variations and the evaluation of medical care outcomes. JAMA. 1988;259:3027–3030. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
